Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Written By Yiran Gan

2024.10.29

Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D. Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M. Vroom, Carly M. Farris, Yihua Ma, Marieke L. de Kam, Igor Radanovic, Maurits F. J. M. Vissers, Dario Mirski, Ghazal Shareghi, Mohammad Shahnawaz, Wolfgang Singer, Philip Kremer, Geert Jan Groeneveld, Hui Jing Yu & Jean-Cosme Dodart 

Nature Medicine volume 30, pages2631–2640 (2024)

https://www.nature.com/articles/s41591-024-03101-8

Yiran Gan
Previous

White matter alterations and their associations with biomarkers and behavior in subjective cognitive decline individuals: a fixel-based analysis
Next

The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment